Feasibility of detecting human immunodeficiency virus type 1 drug resistance in DNA extracted from whole blood or dried blood spots
Authors & affiliation
Kim Steegen, Stanley Lüchters, Els Demecheleer, Kenny Dauwe, K Mandaliya, W Jaoko, Jean Plum, Marleen Temmerman, Chris Verhofstede
Abstract
Due to high cost, availability of human immunodeficiency virus type 1 (HIV-1) drug resistance testing in resource-poor settings is still limited. We therefore evaluated the usefulness of viral DNA extracted from either whole blood or dried blood spots (DBS). Samples were collected from 50 patients receiving therapy and 10 therapy-naive patients. Amplification and sequencing of RNA and DNA was performed using an in-house assay. Protease (PR) and reverse transcriptase (RT) sequences of plasma viral RNA were obtained for 96.6% and 89.7%, respectively, of the 29 patients with a detectable viral load. For cellular viral DNA, useful PR and RT sequences were obtained for 96.6% and 93.1% of the whole-blood-cell samples and for 93.1% and 93.1% of the DBS samples, respectively. For the 31 patients with an undetectable viral load, PR and RT sequences were obtained for 67.7% and 61.3% of the whole-blood-cell DNA preparations and for 54.8% and 58.1% of the DBS DNA preparations, respectively. A good correlation between RNA and DNA sequences was found; most discordances were caused by the detection of mixed amino acids. Of the RT drug-resistant mutations, 13 (38.2%) were seen in RNA only, 6 (17.6%) in DNA only, and 15 (44.1%) in both. Repeated amplification and sequencing of DNA extracts revealed a lack of reproducibility for the detection of drug resistance mutations in a number of samples, indicating a possible founder effect. In conclusion, this study shows the feasibility of genotypic drug resistance testing on whole blood cells or DBS and its possible usefulness for HIV-1 subtyping or examining the overall distribution of drug resistance in a population. For individual patients, RNA sequencing was shown to be superior to DNA sequencing, especially for patients who experienced early treatment failure. The use of DNA extracted from whole blood or DBS for the detection of archived drug resistance mutations deserves further study.
Publication date:
2007
Staff members:
Stanley Luchters
Marleen Temmerman
Link to publication
Attachments
published version.pdf (open)Related publications
Olivier Degomme, Emilie Peeters, Hedwig Deconinck, Alban Ylli, Albana Fico, Gentiana Qirjako, Dorina Ttocaj, Sara De Meyer, Kristien Michielsen, Anna Page, Wina Baeha, Kristi Praptiwi, Miranda van Reeuwijk, Beatriz Manuel, Elin C. Larsson, Carmen Ortiz, Bernardo Vega, Monserrath Jerves, Simukai Shamu, Annemiek Seeuws, Anna Galle, Anne Nobels, Ines Keygnaert, Hazel Barrett, Nina Van Eekert, Tammary Esho, Els Leye, Carles Pericas Escale, Samuel Thuo Kimani, Sofie Thielemans, Dara De Schutter, Remi Moerkerke, Louis De Backer, Viola N. Nyakato, Elizabeth Kemigisha, Wei Hong Zhang, Marleen Temmerman, Lina Hu, Shangchun Wu, Kaiyan Pei, Charlotte Neves de Oliveira, Argyro Chatzinikolaou, Eva Lievens
2022 Barriers and facilitators to cervical cancer screening among under- and neverscreened women in Belgium : a qualitative study on community and healthcare providers’ perspectiveBo Verberckmoes, Elien De Paepe, Janne De Vestele, Heleen Vermandere, Ines Keygnaert, Olivier Degomme
2022 Inhoudelijk eindrapport Opleiding seksueel geweld voor de Family Justice Centers & Ketenaanpak Intrafamiliaal GeweldSaar Baert, Lisa Fomenko, Nele Vaerewijck, Lotte De Schrijver, An-Sofie Van Parys, Ines Keygnaert